How to integrate biologicals in the continuum of care.
Venugopal
B
B
Beatson West of Scotland Cancer Centre, Department of Medical Oncology, Glasgow, UK.
Cassidy
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000235:genetics / Q000628:therapy*; D003875:Drug Eruptions / Q000209:etiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D009154:Mutation / Q000235:genetics; D009362:Neoplasm Metastasis; D011183:Postoperative Complications / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001688:Biological Products; D014408:Biomarkers, Tumor; D066246:ErbB Receptors